Thursday, August 22, 2013
Ocular Surgery News
In a letter to the U.S. Food and Drug Administration, Allergan requested that the agency revise and replace bioequivalence draft guidelines issued on June 20. The FDA accepted public comment on the proposed guidelines until Aug. 19.